非编码RNA多态性和对肺癌疗法的耐药性之间的交叉关系
Samaneh Mollazadeh1, Negar Abdolahzadeh2, Meysam Moghbeli3
1Natural Products and Medicinal Plants Research Center, North Khorasan University of Medical Sciences, Bojnurd, Iran.
Heliyon
|October 13, 2023
概括
非编码RNA多态,如长非编码RNA (lncRNAs) 和微RNA (miRNAs),影响肺癌 (LC) 治疗耐药性. 探索这些遗传变异可能会导致个性化治疗和改善患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
背景情况:
- 肺癌 (LC) 仍然是全球癌症死亡的主要原因.
- 目前的多模式疗法提供有限的成功,预后不佳,患病率高.
- 缺乏有效的生物标志物来预测患者对LC疗法的反应.
研究的目的:
- 审查非编码RNA多态体在肺癌治疗耐药性的作用.
- 探索非编码RNA中的遗传变异作为肺癌治疗的预测生物标记物的潜力.
- 突出基因定型对于制定个性化肺癌治疗策略的重要性.
主要方法:
- 文献综述侧重于非编码RNAs (长非编码RNAs和microRNAs) 和它们的多态.
- 分析遗传变异及其对肺癌治疗耐药性的影响.
- 讨论用于识别相关多态的基因型定型方法.
主要成果:
- 非编码RNA多态,包括lncRNA和miRNA,与获得的耐药性有关.
- 这些非编码RNA的遗传变异在预测治疗疗效方面存在挑战.
- 已知多态的基因定型为识别潜在生物标记物提供了一条途径.
结论:
- 非编码RNA多态是理解和克服肺癌治疗耐药性的有希望领域.
- 进一步研究这些变异的基因定型可能有助于为肺癌患者开发个性化治疗方法.
- 识别遗传标记可能会改善治疗反应和肺癌患者的治疗.
相关概念视频
lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Single Nucleotide Polymorphisms-SNPs
15.2K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
15.2K
RNA Splicing
56.4K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
56.4K
Non-LTR Retrotransposons
11.5K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.5K


